Hexaminolevulinate-mediated photodynamic purging of leukemia cells from BM

Bone Marrow Transplant. 2010 Oct;45(10):1553-61. doi: 10.1038/bmt.2009.382. Epub 2010 Feb 1.

Abstract

Photodynamic therapy (PDT) with porphyrin precursors has been established for tumor treatment. This study aimed at examining applicability of hexaminolevulinate (HAL) for photodynamic purging of leukemic cells from BM grafts and evaluating the clinical relevance of in vitro models. The PDT dose resulting in no colony formation by leukemic cells in vitro, in pure form or in a mixture with BM cells, was insufficient for complete killing of the leukemic cells ex vivo and for the treatment of the leukemia-bearing animals in vivo. The efficacy of HAL-PDT in cell lines in vitro should be verified in clinically relevant in vivo models.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminolevulinic Acid / analogs & derivatives*
  • Aminolevulinic Acid / pharmacology
  • Animals
  • Bone Marrow Cells / chemistry
  • Bone Marrow Cells / drug effects*
  • Bone Marrow Purging / methods*
  • Bone Marrow Transplantation*
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Female
  • Gamma Rays
  • Granulocytes / chemistry
  • Granulocytes / drug effects
  • Leukemia L1210 / mortality
  • Leukemia L1210 / therapy*
  • Mice
  • Mice, Inbred DBA
  • Osmolar Concentration
  • Photochemotherapy
  • Photosensitizing Agents / pharmacology*
  • Protoporphyrins / analysis
  • Survival Analysis
  • Tumor Stem Cell Assay
  • Whole-Body Irradiation / mortality

Substances

  • Photosensitizing Agents
  • Protoporphyrins
  • Aminolevulinic Acid
  • protoporphyrin IX
  • 5-aminolevulinic acid hexyl ester